| Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, Kailayangiri S, Gutierrez Suburu ME, Strassert CA, Schenk M, Greune L, Rüter C, Dersch P, Hartmann W, Rossig C, Neri D, Müller-Tidow C, Schwöppe C, Schliemann C, Khandanpour C, Lenz G, Berdel WE, Bäumer S. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol 2022;15Abstract
|
| Baumer N, Tiemann J, Scheller A, Meyer T, Wittmann L, Suburu MEG, Greune L, Peipp M, Kellmann N, Gumnior A, Brand C, Hartmann W, Rossig C, Muller-Tidow C, Neri D, Strassert CA, Ruter C, Dersch P, Lenz G, Koeffler HP, Berdel WE, Baumer S. Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene 2022;41: 2210-2224. Abstract
|
| Faust A, Baumer N, Schlutermann A, Becht M, Greune L, Geyer C, Ruter C, Margeta R, Wittmann L, Dersch P, Lenz G, Berdel WE, Baumer S. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). Angew Chem Int Ed Engl 2022;61: e202109769. Abstract
|
| Angenendt L, Hilgefort I, Mikesch J-H, Schluter B, Berdel WE, Lenz G, Stelljes M, Schliemann C. Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Ann Hematol 2021;100: 1871-1878. Abstract
|
| Berdel AF, Schwöppe C, Brand C, Harrach S, Brömmel K, Hintelmann H, Lenz G, Liersch R, Heinzow H, Schliemann C, Mesters RM, Berdel WE, Kessler T. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction. Cancers 2021;13: 2841. Abstract
|
| Gerwing M, Krahling T, Schliemann C, Harrach S, Schwoppe C, Berdel AF, Klein S, Hartmann W, Wardelmann E, Heindel WL, Lenz G, Berdel WE, Wildgruber M. Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease. Cancers (Basel) 2021;13Abstract
|
| Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan W-C, Meffre E, Martin T, Muschen M. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Mol Cell 2021;81: 2094-2111.e9. Abstract
|
| Schliemann C, Hemmerle T, Berdel AF, Angenendt L, Kerkhoff A, Hering JP, Heindel W, Hartmann W, Wardelmann E, Chawla SP, de Braud F, Lenz G, Neri D, Kessler T, Berdel WE. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. European Journal of Cancer 2021;150: 143-154. Abstract
|
| Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch J-H, Lenz G, Schafers M, Neri D, Stelljes M, Berdel WE. Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. Br J Haematol 2021;192: e148-e151. Abstract
|
| Brand C, Greve B, Bolling T, Eich HT, Willich N, Harrach S, Hintelmann H, Lenz G, Mesters RM, Kessler T, Schliemann C, Berdel WE, Schwoppe C. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma. PLoS One 2020;15: e0229271. Abstract
|
| Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AD, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE. First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers 2020;12: 1488. Abstract
|
| Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischaluck J, Lenz G, Wardelmann E, Mesters RM, Schwoppe C, Berdel WE, Hartmann W, Schliemann C. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. Transl Oncol 2018;11: 1271-1282. Abstract
|
| Mikesch J-H, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Kohler G, Lenz G, Muller-Tidow C, Berdel WE, Arteaga M-F. Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. Eur Respir J 2018;52: 1701637. Abstract
|
| Spukti EU, Schmidt LH, Schulze A, Schliemann C, Gorlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A. (90) Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. Eur J Haematol 2018;101: 514-521. Abstract
|
| Dai B, Grau M, Juilland M, Klener P, Horing E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Johrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood 2017;129: 333-346. Abstract
|
| Erdmann T, Klener P, Lynch JT, Grau M, Vockova P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 2017;130: 310-322. Abstract
|
| Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Kessler T, Kerkhoff A, Lenz G, Berdel WE. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Cancer Res Treat 2017;49: 548-552. Abstract
|
| Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Gorlich D, Marra A, Hillejan L, Muller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwoppe C, Hartmann W. Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS One 2017;12: e0177146. Abstract
|
| Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer 2017;113: 121-127. Abstract
|
| Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann M-L, Kreher S, Kochert K, Krappmann D, Klapper W, Hummel M, Wenzel S-S, Lenz G, Janz M, Dorken B, Siebert R, Mathas S. Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Leukemia 2017;31: 602-613. Abstract
|
| Bognar MK, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott G, Lenz G, Hauck SM, Krappmann D. Oncogenic CARMA1 couples NF-kappaB and beta-catenin signaling in diffuse large B-cell lymphomas. Oncogene 2016;35: 4269-4281. Abstract
|
| Erdmann T, Lenz G. Approaching resistance to ibrutinib in diffuse large B-cell lymphoma. Leuk Lymphoma 2016;57: 1254-1255. Abstract
|
| Gatjen M, Brand F, Grau M, Gerlach K, Kettritz R, Westermann J, Anagnostopoulos I, Lenz P, Lenz G, Hopken UE, Rehm A. Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. Cancer Res 2016;76: 5253-5265. Abstract
|
| Juilland M, Gonzalez M, Erdmann T, Banz Y, Jevnikar Z, Hailfinger S, Tzankov A, Grau M, Lenz G, Novak U, Thome M. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood 2016;127: 1780-1789. Abstract
|
| Lange J, Lenz G, Burkhardt B. Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications. Expert Rev Hematol 2016: 1-13. Abstract
|
| Lenz G. Novel NF-kappaB regulator in ABC DLBCL. Blood 2016;127: 2785-2786. Abstract
|
| Pohlen M, Groth C, Sauer T, Gorlich D, Mesters R, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Berdel WE, Stelljes M. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). Bone Marrow Transplant 2016;51: 1441-1448. Abstract
|
| Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch J-H, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Gorlich D, Berdel WE. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. Haematologica 2016;101: 1208-1215. Abstract
|
| Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt ML, Mah N, Weilemann A, Grau M, Groning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Muller-Tidow C, Rosenbauer F. Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. Embo J 2016;35: 2399-2416. Abstract
|
| Stucke-Ring J, Ronnacker J, Brand C, Holtke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wunsch B, Muller-Tidow C, Mesters RM, Schwoppe C, Berdel WE. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Oncotarget 2016;7: 82458-82472. Abstract
|
| Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G. The molecular pathogenesis of mantle cell lymphoma. Leuk Lymphoma 2016: 1-8. Abstract
|
| Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G, Ruland J. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation. Proc Natl Acad Sci U S A 2015;112: E7230-8. Abstract
|
| Lenz G. Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications. Cancers (Basel) 2015;7: 811-822. Abstract
|
| Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dorken B, Chu Y-W, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015;29: 1578-1586. Abstract
|
| Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dorken B, Dirnhofer S, Mathas S, Janz M, Emre NCT, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 2015;125: 124-132. Abstract
|
